Vertaling van "the value of forming " (Nederlands → Frans) :

This produced a first list of core elements for becoming a highly effective model organisation, and a number of powerful ideas emerged, such as the need for multidisciplinarity and the value of forming “centres of excellence” or spearheads (see below) within the FAMHP.
This produced a first list of core elements for becoming a highly effective model organisation, and a number of powerful ideas emerged, such as the need for multidisciplinarity and the value of forming “centres of excellence” or spearheads (see below) within the FAMHP.

The values nurtured within the FAMHP are carefully selected, and form the unifying theme in our day-to-day activities: ●● Professionalism ●● Integrity ●● Sincerity and transparency ●● Comprehensiveness ●● Participation
The values nurtured within the FAMHP are carefully selected, and form the unifying theme in our day-to-day activities: ●● Professionalism ●● Integrity ●● Sincerity and transparency ●● Comprehensiveness ●● Participation

As a result of the 37% decline in Alcon’s share price at the end of 2008 to USD 89.19 from the price paid for the initial 24.8% stake, Novartis performed an impairment test on the investment’s carrying value. This test assessed the “value in use” to Novartis of this strategic investment by valuing estimated discounted cash flows and future dividend streams from Alcon against the “fair value less costs to sell” of this stake, as measured by the closing price on December 31, 2008, on the NYSE for the 23% publicly traded Alcon shares.
Ce test consiste à comparer la « valeur d’utilité » de cet investissement stratégique pour Novartis sur la base d’une estimation des valeurs actualisées des flux de trésorerie futurs et des flux des dividendes futurs relatifs à la part détenue par Novartis avec la « juste valeur moins les coûts de la vente » sur la base du cours de clôture du 31 décembre 2008 des 23% d’actions Alcon négociées à la Bourse de New York.

Since the higher of the estimated “value in use” and the “fair value less costs to sell” exceeded the carrying value of USD 140.68 per share, no impairment charge was recorded.
Comme la valeur la plus élevée entre la « valeur d’utilité » et la « juste valeur moins les coûts de la vente » estimées était supérieure à la valeur au bilan d’USD 140,68 par action, aucune charge pour perte de valeur n’a été comptabilisée.

Based on an evaluation of publicly available information about Alcon during the first half of 2009, no factors indicated that the “value in use” of this strategic investment to Novartis has fallen below the current carrying value of USD 136.84 per share (The revised carrying value from the previous level of USD 140.58 at the end of the first quarter of 2009 takes into account dividends paid in 2009 as well as other equity accounting adjustments).
Sur la base d’une évaluation des informations publiées sur Alcon au cours du premier semestre 2009, aucun facteur n’indiquait que pour Novartis, la valeur d’utilité de cet investissement stratégique était tombée en dessous de la valeur comptable d’USD 136,84 par action (cette valeur comptable inscrite au bilan et révisée par rapport à la valeur d’USD 140,58 à la fin du premier trimestre 2009, suite aux dividendes payés en 2009 ainsi que d’autres ajustements comptables résultant de l’application de la méthode de la mise en équivalence).

MISSION, VISION AND AMBITION, VALUES AND ROLE 5 Mission 6 Vision and ambition 6 Values 6 Role 6
MISSION, VISION AND AMBITION, VALUES AND ROLE 5 Mission 6 Vision and ambition 6 Values 6 Role 6

Narcotics forms The graph below shows the fluctuation in the number of narcotics forms issued per month.
Narcotics forms The graph below shows the fluctuation in the number of narcotics forms issued per month.

MISSION, VISION AND AMBITION, VALUES AND ROLE
MISSION, VISION AND AMBITION, VALUES AND ROLE

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

Antwoord: 1 Grouping voor 1 MA: 1 module 1 met o.a. 1 cover letter + 1 gemeenschappelijk application form voor de hele groep (met duidelijke opsomming van de individuele variaties in de groep: nummer uit de guideline + korte omschrijving voor elke individuele variatie) + één Module 2,3,4, of 5 (naargelang wat van toepassing is) waarin alle aangevraagde wijzigingen zijn opgenomen.
Réponse : 1 Grouping pour 1 MA : 1 module 1 avec e.a. 1 cover letter + 1 application form commun à l’ensemble du groupe (avec une énumération claire des variations individuelles dans le groupe : numéro provenant de la guideline + brève description pour chaque variation individuelle) + un Module 2, 3, 4, ou 5 (en fonction de ce qui s’applique) reprenant toutes les modifications demandées.